The Clover x Shark Tank Summit Reveals Full Speaker Line-Up and Programming for First-Ever Live Event in Las Vegas from September 28-30
This year's Clover x Shark Tank Summit will feature previously announced business tycoons – the 'Sharks' from the hit reality TV show, including Barbara Corcoran, Robert Herjavec, Daymond John, Kevin O'Leary, Daniel Lubetzky and two exciting guest Sharks, Rashaun Williams, venture capitalist and financial literacy activist, and Allison Ellsworth, co-founder of poppi, who recently sold poppi for close to $2B. Additional notable speakers include Mark Cuban, Tabitha Brown and Gary Vaynerchuck. The lineup will also include world famous entrepreneurs, dealmakers, brand builders, company founders, and more, who will speak on all things small business, including raising capital, community, mastering your business pitch, talent trends, marketing, and much more.
Newly announced to the star-studded line-up of speakers from 'Shark Tank' are Emmy®-nominated Mindy Zemrak, Supervising Casting Producer of 'Shark Tank,' Jim Tselikis and Sabin Lomac, co-founders of Cousins Maine Lobster, and one of Barbara's Corcoran's most popular and successful 'Shark Tank' investments, David Heath and Randy Goldberg, co-founders of Bombas, the most successful 'Shark Tank' company in retail sales. Additional prominent speakers from the world of business are Jay Bailey, President and CEO of Russell Innovation Center for Entrepreneurs, Katie Kirkpatrick, President & CEO of Metro Atlanta Chamber, TJ Bennett, Co-owner and CEO of Sole Play, Alison Lands and Khalilah 'KO' Olokunola of Jobs For The Future, Mike Hofman, Editor-in-Chief of Inc., Melissa Bouma, CEO of Manifest and Jess Sims, Peloton Instructor, ESPN Reporter & GMA Contributor.
Throughout the three-day event, attendees will gain insights from experts and take a deep dive into what it takes to start, grow and scale a business ranging from sessions such as:
Shark-Sized Confidence: Invest in You – a powerful fireside chat on investing in yourself, self-care, resilience, and staying grounded while you grow.
– a powerful fireside chat on investing in yourself, self-care, resilience, and staying grounded while you grow. The Big Catch: Raising Capital with a Shark Tank Mindset – learn how to think beyond the bank with nontraditional funding routes to raising capital that still pack power.
– learn how to think beyond the bank with nontraditional funding routes to raising capital that still pack power. Swim With Your Pack: Why Community is Your Strategic Advantage – a powerhouse session on how innovation, leadership, and public-private partnerships can fuel businesses that move communities forward.
– a powerhouse session on how innovation, leadership, and public-private partnerships can fuel businesses that move communities forward. For That Reason, I'm In: Master the Pitch – an interactive workshop to help you master the art of the pitch, from funding fundamentals to real-time demos, these tips will help you win over investors, banks, and more.
– an interactive workshop to help you master the art of the pitch, from funding fundamentals to real-time demos, these tips will help you win over investors, banks, and more. Think Like a Shark: From Scrappy to Scalab l e —Your Zero to Hero Game Plan – a high-powered session covering the 10 must-dos before raising capital, plus insider tips on VC funds and more.
l —Your Zero to Hero Game Plan – a high-powered session covering the 10 must-dos before raising capital, plus insider tips on VC funds and more. Make Them Bite: Branding that Grows Your Business – a powerhouse panel on the new rules of branding and marketing, delivering strategies entrepreneurs can use to grow their business.
– a powerhouse panel on the new rules of branding and marketing, delivering strategies entrepreneurs can use to grow their business. Catch the Best: How to Net Top Talent – an in-depth view on how to hire, inspire, and retain top talent.
– an in-depth view on how to hire, inspire, and retain top talent. The Final Pitch – The conference culminates in an exciting celebratory moment when a select group of entrepreneurs will take to the stage to pitch live before an audience and a distinguished panel – including Sharks!
Ahead of the Clover x Shark Tank Summit, small business owners can enter to win an Access Pass for a chance to participate in the event. The entry period runs through August 11. Entrepreneurs looking to elevate their businesses can visit Clover.com for complete details.
To learn more about Clover and how the brand is providing solutions for small businesses, including the Clover x Shark Tank Summit, visit Clover.com and follow @clovercommerce on Instagram, X, Facebook, and LinkedIn with hashtag #CloverxSharkTankSummit.
Since launching in 2001 as 'Money Tigers' on Nippon TV in Japan and known around the world under titles including 'Dragons' Den,' 'Shark Tank,' and 'Lions' Den,' the Sony Pictures Television-distributed format has become the world's number one adapted business reality television show, in terms of the number of territories launched. Produced in territories on every continent, the format sees aspiring entrepreneurs pitch to secure investment from some of the top names in the business world.
About Fiserv
Fiserv, Inc. (NYSE: FI), a Fortune 500 company, moves more than money. As a global leader in payments and financial technology, the company helps clients achieve best-in-class results through a commitment to innovation and excellence in areas including account processing and digital banking solutions; card issuer processing and network services; payments; e-commerce; merchant acquiring and processing; and Clover®, the world's smartest point-of-sale system and business management platform. Fiserv is a member of the S&P 500® Index and one of Fortune® World's Most Admired Companies™. Visit fiserv.com and follow on social media for more information and the latest company news.
About Shark Tank
The recipient of five Emmy Awards for Outstanding Structured Reality Program, ABC's 'Shark Tank,' premiering its 17th season this fall, features the Sharks – tough, self-made, multimillionaire and billionaire tycoons – as they invest in America's best businesses and products. The Sharks give people from all walks of life the chance to chase the American Dream and potentially secure life-changing business deals. The Sharks are real estate mogul Barbara Corcoran; prolific CPG investor and self-made inventor of retail products Lori Greiner; cyber-security technology innovator Robert Herjavec; fashion and branding expert Daymond John; venture capitalist Kevin O'Leary; and philanthropist and founder of KIND Snacks and the Builders, Daniel Lubetzky. Mark Burnett, Clay Newbill, Yun Lingner, Max Swedlow, Brandon Wallace, Barbara Corcoran, Lori Greiner, Robert Herjavec, Daymond John, Kevin O'Leary, Barry Poznick, and Phil Gurin are the executive producers of 'Shark Tank,' which is based on the Japanese 'Dragons' Den' format, created by Nippon TV. The series is produced by MGM Television, a division of Amazon MGM Studios, in association with Sony Pictures Television.
About Sony Pictures Television
Sony Pictures Television (SPT) is one of the television industry's leading content providers, producing, distributing and carrying programming worldwide in every genre and for every platform. In addition to managing one of the industry's largest libraries of award-winning feature films, television shows and formats, SPT is home to a thriving global content business, operating a robust portfolio of wholly-owned and joint-venture production companies across the U.S., Europe, Latin America, and Asia Pacific, as well as linear and digital channels around the world. SPT is a Sony Pictures Entertainment Company, a subsidiary of Tokyo-based Sony Group Corporation.
FI-G
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
The Open Group Launches The Open Group Open Digital Transformation™ Forum
SAN FRANCISCO--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. 'The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation,' commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. 'By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices.' Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. 'Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge,' said Steve Nunn, President and CEO of The Open Group. 'Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment.' To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries.
Business Wire
6 minutes ago
- Business Wire
Bureau Veritas Partners with IFC's Building Resilience Index to Expand Resilience Verification Services Globally
PARIS--(BUSINESS WIRE)-- Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), has signed the first global verifier agreement to expand the reach and impact of the Building Resilience Index (BRI). Under this agreement, Bureau Veritas will serve as a verification partner for BRI across key emerging markets in Latin America, Africa, and East Asia and the Pacific. An innovation of IFC, a member of the World Bank Group, BRI is a web-based framework designed to help developers, investors, and policymakers identify risks to buildings posed by natural hazards and assess, improve, and disclose their resilience. Through this partnership with Bureau Veritas, BRI users will gain greater access to high-quality, third-party verification of climate-resilient construction practices, expanding trust and adoption of the tool in vulnerable regions where business continuity is increasingly threatened by extreme weather and related hazards. "We are delighted to become a Global Verifier of the Building Resilience Index. As climate phenomena intensify, it has become essential to integrate climate change adaptation into assets strategy. The signing of our global agreement with the International Finance Corporation marks a crucial step,' said Marc Roussel, Executive Vice President, Urbanization and Assurance at Bureau Veritas. 'Bureau Veritas has a long history as an independent third party mitigating natural and climate risks. Our network of experts will add a layer of trust so that stakeholders can rely on Building Resilience Index to evaluate vulnerability and effectiveness of adaptation strategies, worldwide.' In recent years, physical risks such as floods, cyclones, heatwaves, fires, earthquakes and landslides have posed major threats to business operations, disrupting supply chains, displacing workers and jobs, hurting productivity, and impacting insurance and financing terms. The BRI-Bureau Veritas partnership responds to a growing demand from businesses and governments for reliable tools that support risk mitigation, asset protection, and long-term economic stability. 'As businesses face increased risks to assets and infrastructure from natural disasters, the ability to assess and verify resilience is becoming a crucial element of operational and investment strategy,' said Diep Nguyen-van Houtte, Senior Manager of Climate Business at IFC. 'This partnership with Bureau Veritas strengthens the Building Resilience Index by ensuring that more clients—particularly in high-risk geographies—can benefit from credible, independently-verified insights into the resilience of their properties, adding a new tool to their climate adaptation arsenal.' By offering third-party verification through Bureau Veritas, the Building Resilience Index helps stakeholders: Protect operational continuity by identifying risks early and designing for resilience Safeguard jobs and livelihoods by minimizing disruption in vulnerable communities Enhance access to capital through better risk ratings and insurance alignment Improve public trust and accountability through independent performance validation This partnership builds on IFC's broader commitment to integrating adaptation into private sector development and enabling practical, market-driven solutions for climate resilience. BRI is funded by the Australian Government and was developed and piloted with seed funding from the Government of the Netherlands and the Rockefeller Foundation, in cooperation with leading organizations including the ARISE Private Sector Alliance for Disaster Resilient Societies, Build Change, FM Global, the Global Facility for Disaster Reduction and Recovery, Miyamoto International, and Resilience Action Fund. About Bureau Veritas: Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. About IFC: IFC — a member of the World Bank Group — is the largest global development institution focused on the private sector in emerging markets. We work in more than 100 countries, using our capital, expertise, and influence to create markets and opportunities in developing countries. In fiscal year 2024, IFC committed a record $56 billion to private companies and financial institutions in developing countries, leveraging private sector solutions and mobilizing private capital to create a world free of poverty on a livable planet. For more information, visit
Business Wire
36 minutes ago
- Business Wire
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg ®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg ® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: 'We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg ® (MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy.' Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
